Compare CURI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURI | IMUX |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | 42 | 66 |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.9M | 152.6M |
| IPO Year | N/A | 2013 |
| Metric | CURI | IMUX |
|---|---|---|
| Price | $2.46 | $11.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.83 | ★ $36.00 |
| AVG Volume (30 Days) | 326.2K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 10.36% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.91 | N/A |
| Revenue Next Year | $12.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.81 | $0.51 |
| 52 Week High | $7.15 | $13.30 |
| Indicator | CURI | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 29.55 | 77.75 |
| Support Level | N/A | $0.75 |
| Resistance Level | $3.56 | N/A |
| Average True Range (ATR) | 0.17 | 1.03 |
| MACD | -0.05 | 0.13 |
| Stochastic Oscillator | 15.64 | 72.41 |
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.